Blockbuster drugs grouped by the year the first US generic or biosimilar can launch. Each block is sized by the drug's 2025 worldwide sales, the revenue its owner has to replace.
Counts only the drugs tracked here, so a company's full exposure can be higher. For shared drugs, each company is credited with the revenue it reports from that drug, so nothing is counted twice. Totals are whole-company revenue.
Acquisitions of $1B or more closed since 2023: Pfizer $51.0B · Merck $39.4B · AbbVie $33.2B · Amgen $27.8B · Bristol Myers Squibb $24.4B · Novartis $23.6B · Johnson & Johnson $21.9B · Eli Lilly $21.6B · Sanofi $17.1B · Gilead $15.3B · Vertex $14.9B · Roche $13.2B · Astellas $5.9B · Novo Nordisk $4.7B · AstraZeneca $4.3B · Takeda $4.0B · Incyte $1.25B. Each company page sets these against its revenue at risk. See all deals →
Formycon and Zydus's FYB206 is the first publicly announced Keytruda biosimilar under FDA review; a decision is expected in Q3 2027. Merck's primary US compound patent expires in December 2028. Formycon and Zydus
| US LOE | Drug | Company | Area | 2025 sales | Date basis | Copies lined up | Medicare price | Note | Sources |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | Entresto | Novartis | Cardiometabolic | $7.7B | Generics launched | Copies on the US market | 2026 only · −53% | US generics entered in Q3 2025. | Novartis Q4 2025 CMS: negotiated prices for 2026 |
| 2025 | Stelara | Johnson & Johnson | Immunology | $6.1B | Biosimilars launched | Copies on the US market | 2026 only · −66% | US biosimilars from Jan 2025. Sales were $10.4B in 2024, before entry. | J&J FY2025 CMS: negotiated prices for 2026 |
| 2025 | Xarelto | Bayer / Johnson & Johnson | Cardiometabolic | ≈$5.3B | Generics launched | Copies on the US market | 2026 only · −62% | The first US generic launched in March 2025. Sales: J&J in the US ($2.63B) plus Bayer elsewhere (EUR 2.34B, down a third as generics spread in Europe and Japan). | J&J 10-K 2025 Bayer Annual Report 2025 CMS: negotiated prices for 2026 |
| 2025 | Prolia | Amgen | Other | $4.4B | Biosimilars launched | Copies on the US market | – | Denosumab biosimilars launched in the US from mid-2025. Bone health. | Amgen FY2025 |
| 2025 | Xgeva | Amgen | Oncology | $2.1B | Biosimilars launched | Copies on the US market | – | Amgen's US patents expired in February 2025 and denosumab biosimilars launched later that year. Prevents bone complications in cancer. | Amgen 10-K 2025 |
| 2026 | Farxiga | AstraZeneca | Cardiometabolic | $8.4B | Generics launched | Copies on the US market | 2026 · −68% | FDA approved the first US generics on 6 April 2026. | AZ FY2025 FDA CMS: negotiated prices for 2026 |
| 2026 | Xolair | Roche / Novartis | Immunology | ≈$5.4B | Biosimilars launched | Copies on the US market | 2028 · under review | Celltrion launched Omlyclo, the first US biosimilar, on 5 October 2026 under a settlement with Genentech. Sales: Roche in the US (CHF 3.08B, up 32% on food allergy use) plus Novartis elsewhere ($1.72B). | Roche Finance Report 2025 Novartis 20-F 2025 Celltrion launch release CMS: drugs selected for 2028 |
| 2026 | Perjeta | Roche | Oncology | ≈$3.6B | Company guidance | Approved, waiting to launch | – | Roche says its primary US and EU patents expired in Q2 2025 and expects the first biosimilars in 2026. Sales CHF 2.97B, down 13% as patients move to Phesgo, which combines Perjeta and Herceptin in one injection. | Roche Finance Report 2025 |
| 2026 | Pomalyst | Bristol Myers Squibb | Oncology | $2.7B | Generics launched | Copies on the US market | 2027 · −60% | US generics launched March 2026 under settlements. | BMS FY2025 CMS: negotiated prices for 2027 |
| 2026 | Simponi | Johnson & Johnson | Immunology | $2.7B | Company guidance | Approved, waiting to launch | – | The FDA approved the first biosimilars, Bio-Thera's Immgolis, in May 2026, and Accord BioPharma plans a US launch in Q4 2026. Sales include the IV form Simponi Aria. | Accord BioPharma release J&J 10-K 2025 |
| 2026 | Januvia | Merck | Cardiometabolic | $2.5B | Generics launched | Copies on the US market | 2026 · −79% | US generics launched in May 2026 under settlements with more than two dozen companies. Sales include Janumet ($0.94B); Januvia alone was $1.60B. | Merck 10-K 2025 Merck 10-Q, Q2 2026 CMS: negotiated prices for 2026 |
| 2026 | Opsumit | Johnson & Johnson | Other | $2.3B | Generics launched | Copies on the US market | – | US generics entered late in Q2 2026, J&J says. Pulmonary arterial hypertension. Sales include Opsynvi, which combines macitentan with tadalafil. | J&J 10-Q, Q2 2026 J&J 10-K 2025 |
| 2027 | Xtandi | Astellas / Pfizer | Oncology | ≈$6.0B | Patent-expiry estimate | Approved, waiting to launch | 2027 · −48% | Last listed US patent expires August 2027. Sales: Astellas global, ¥960.8B (fiscal year to March 2026). | Fierce Pharma CMS: negotiated prices for 2027 |
| 2027 | Trulicity | Eli Lilly | Cardiometabolic | $4.3B | Company guidance | Early development | 2028 · pending | Lilly 10-K: US compound patent and data protection end 2027. | Lilly 10-K CMS: drugs selected for 2028 |
| 2027 | Ibrance | Pfizer | Oncology | $4.1B | Patent-expiry estimate | Filed with the FDA | 2027 · −50% | US patent term extended to March 2027, and pediatric exclusivity to September 2027. | Pfizer FY2025 Pfizer PTE FDA Orange Book data files CMS: negotiated prices for 2027 |
| 2027 | Trelegy | GSK | Other | ≈$3.9B | Patent-expiry estimate | Filed with the FDA | 2027 · −73% | GSK's latest US compound patent expires in 2027, but inhaler and formulation patents run to 2030 (2031 with pediatric exclusivity). Sales GBP 2,986M. | GSK 20-F 2025 FDA Orange Book: Trelegy patents CMS: negotiated prices for 2027 |
| 2027 | Lynparza | AstraZeneca / Merck | Oncology | $3.3B | Company guidance | Tentatively approved | – | Merck 10-K: US basic patent 2027. AstraZeneca and Merck have sued generic filers since 2023. Sales as reported by AstraZeneca; Merck books $1.5B of alliance revenue. | Merck 10-K 2025 AstraZeneca 20-F 2025 |
| 2028 | Keytruda | Merck | Oncology | $31.7B | Company guidance | Filed with the FDA | – | Primary US compound patent expires December 2028. Includes subcutaneous Keytruda Qlex. EU exclusivity to 2031. | Merck FY2025 Merck 10-K |
| 2028 | Eliquis | Bristol Myers Squibb / Pfizer | Cardiometabolic | $14.4B | Settlement / court date | Approved, waiting to launch | 2026 · −56% | US generics barred until 1 April 2028 after patent win and settlements. EU generics earlier. Sales as reported by BMS; Pfizer separately books $8.0B of alliance and product revenue. | BMS FY2025 CMS: negotiated prices for 2026 |
| 2028 | Opdivo | Bristol Myers Squibb | Oncology | $10.1B | Company guidance | Filed with the FDA | – | BMS guides to US biosimilar entry from 2028. Subcutaneous Opdivo Qvantig may extend the franchise. | BMS FY2025 |
| 2028 | Gardasil | Merck | Vaccines | $5.2B | Patent-expiry estimate | No US filing found | – | Key patents expire around 2028. Sales fell 39% in 2025 on weaker China demand. | Merck FY2025 |
| 2028 | Tecentriq | Roche | Oncology | ≈$4.3B | Patent-expiry estimate | No US filing found | – | The 12-year US biologic exclusivity ends in May 2028. Roche does not publish Tecentriq's patent dates, which may run later. Sales CHF 3.57B. | Roche Finance Report 2025 FDA Purple Book |
| 2028 | Jakafi | Incyte | Oncology | $3.1B | Company guidance | Filed with the FDA | – | Incyte 10-K: estimated minimum US market exclusivity 2028, when the composition patents expire. Jakafi is 60% of Incyte's revenue. | Incyte 10-K 2025 |
| 2028 | Otezla | Amgen | Immunology | $2.3B | Settlement / court date | Approved, waiting to launch | 2027 · −65% | A court barred generics until the key US patent expires on 16 February 2028, and Amgen says pediatric exclusivity on that patent runs to 16 August 2028. Amgen settled with other filers. A newer extended-release version has patents to 2042. | Amgen 10-K 2025 Fierce Pharma CMS: negotiated prices for 2027 |
| 2029 | Darzalex | Johnson & Johnson | Oncology | $14.3B | Patent-expiry estimate | In clinical trials | – | Core US patents expire 2029. Formulation patents on subcutaneous Darzalex Faspro run longer. | J&J FY2025 |
| 2029 | Jardiance | Boehringer Ingelheim / Eli Lilly | Cardiometabolic | ≈$9.9B | Company guidance | Approved, waiting to launch | 2026 · −66% | Lilly's 10-K puts US compound patent expiry at 2029, including pediatric exclusivity; later use patents run to 2034. Sales: Boehringer Ingelheim, EUR 8.8B for the Jardiance family; Lilly separately books $3.4B. | Boehringer Ingelheim FY2025 Lilly 10-K 2025 CMS: negotiated prices for 2026 |
| 2029 | Ocrevus | Roche | Neuroscience | ≈$8.4B | Patent-expiry estimate | In clinical trials | – | Main US patent protection runs to March 2029. Sales CHF 7.01B. | Roche FY2025 |
| 2029 | Cosentyx | Novartis | Immunology | $6.7B | Patent-expiry estimate | In clinical trials | 2028 · pending | Key exclusivities expected to end around 2029. | Novartis Q4 2025 CMS: drugs selected for 2028 |
| 2029 | Shingrix | GSK | Vaccines | ≈$4.8B | Patent-expiry estimate | No US filing found | – | GSK's 20-F lists the main US patent to 2029. Sales GBP 3.6B; the US share is falling as fewer unvaccinated adults remain, and two thirds of sales now come from outside the US. | GSK 20-F 2025 |
| 2029 | Vraylar | AbbVie | Neuroscience | $3.6B | Patent-expiry estimate | Approved, waiting to launch | 2027 · −44% | The compound patent runs to June 2029 with pediatric exclusivity; a second compound and use patent runs to March 2030. Settlement terms with generic makers have not been disclosed. | AbbVie 10-K 2025 FDA Orange Book: Vraylar patents CMS: negotiated prices for 2027 |
| 2029 | Repatha | Amgen | Cardiometabolic | $3.0B | Patent-expiry estimate | No US filing found | – | Amgen 10-K: US antibody patent expires 27 August 2029; a methods-of-treatment patent runs to May 2032. | Amgen 10-K 2025 |
| 2029 | Nucala | GSK | Immunology | ≈$2.6B | Patent-expiry estimate | In clinical trials | – | GSK's 20-F lists the latest US molecule patent to 2029, with other patents to 2036. The 12-year US biologic exclusivity ends in November 2027. Sales GBP 2.01B, up 15% at constant currency. | GSK 20-F 2025 FDA Purple Book |
| 2029 | Enbrel | Amgen | Immunology | $2.2B | Settlement / court date | Approved, waiting to launch | 2026 · −67% | Court-upheld patents block approved biosimilars until April 2029. | Amgen FY2025 GaBI CMS: negotiated prices for 2026 |
| 2030 | Taltz | Eli Lilly | Immunology | $3.6B | Company guidance | In clinical trials | – | Lilly 10-K: US compound patent 2030; US biologics data protection runs to 2028. | Lilly 10-K 2025 |
| 2031 | Dupixent | Sanofi / Regeneron | Immunology | $17.8B | Company guidance | In clinical trials | – | Extended US patent runs to 28 March 2031. Sanofi plans to defend exclusivity beyond that. | Regeneron FY2025 Fierce Pharma |
| 2031 | Vyndaqel | Pfizer | Cardiometabolic | $6.4B | Settlement / court date | Filed with the FDA | – | April 2026 settlements extend the effective US patent expiry for Vyndamax to 1 June 2031, subject to a case against Apotex that is still going; Pfizer had expected US sales to start falling in 2029. Sales are the Vyndaqel family (Vyndaqel and Vyndamax), for a rare heart disease. | Pfizer Q1 2026 results Pfizer 10-Q, Q2 2026 |
| 2031 | Imfinzi | AstraZeneca | Oncology | $6.1B | Company guidance | Early development | – | AstraZeneca 20-F: US patent protection expected to 2031. | AstraZeneca 20-F 2025 |
| 2031 | Verzenio | Eli Lilly | Oncology | $5.7B | Company guidance | No US filing found | 2028 · pending | Lilly 10-K: US compound patent 2031. | Lilly 10-K 2025 CMS: drugs selected for 2028 |
| 2031 | Tremfya | Johnson & Johnson | Immunology | $5.2B | Company guidance | In clinical trials | – | J&J 10-K: US composition patent family projected to expire in 2031. Sales grew 40% in 2025, which J&J attributes to share gains and market growth. | J&J 10-K 2025 |
| 2031 | Kisqali | Novartis | Oncology | $4.8B | Company guidance | No US filing found | 2028 · pending | Novartis 20-F: US compound patent 2031. Sales grew 58% in 2025. | Novartis 20-F 2025 CMS: drugs selected for 2028 |
| 2031 | Kesimpta | Novartis | Neuroscience | $4.4B | Company guidance | Early development | – | Novartis 20-F: US compound patent 2031 (already expired in Europe). Multiple sclerosis; sales grew 37% in 2025. | Novartis 20-F 2025 |
| 2031 | Invega Sustenna | Johnson & Johnson | Neuroscience | $3.8B | Patent-expiry estimate | Filed with the FDA | – | The one listed US patent, a dosing patent, runs to January 2031 and was upheld at trial against Tolmar; J&J has since won or settled against every challenger. Sales include the longer-acting Invega Trinza and the ex-US brands Xeplion and Trevicta. | J&J 10-K 2025 FDA Orange Book: Invega Sustenna patents Law360: J&J, Tolmar settle |
| 2031 | Descovy | Gilead | Infectious disease | $2.8B | Company guidance | Approved, waiting to launch | – | Gilead 10-K: US patent expiry 2031 (Europe 2027). Gilead sued Cipla in February 2026 over a patent challenge. HIV treatment and prevention. | Gilead 10-K 2025 |
| 2031 | Reblozyl | Bristol Myers Squibb | Other | $2.3B | Company guidance | No US filing found | – | BMS estimates US exclusivity to 2031, based on regulatory exclusivity; a method-of-treatment patent with term restoration runs to 2033. Anemia in MDS and beta thalassemia. | BMS 10-K 2025 |
| 2031 | Cabometyx | Exelixis | Oncology | $2.1B | Settlement / court date | Approved, waiting to launch | – | Settlements with Teva and Cipla allow US generics from 1 January 2031; a court upheld other patents against MSN. US sales, recorded by Exelixis. | Exelixis 10-K 2025 Fierce Pharma |
| 2032 | Ozempic | Novo Nordisk | Cardiometabolic | ≈$19.3B | Company guidance | Tentatively approved | 2027 · −71% | Novo guides to US compound patent expiry in 2032. Generics launched in India and Canada in 2026 as patents lapsed there. Sales DKK 127.1B. | Novo AR 2025 Novo Q1 2026 (India generics) Dr. Reddy's (Canada launch) CMS: negotiated prices for 2027 |
| 2032 | Wegovy | Novo Nordisk | Cardiometabolic | ≈$12.0B | Company guidance | Filed with the FDA | 2027 · −71% | Same molecule as Ozempic (semaglutide), sold for obesity. Novo: US compound patent expiry 2032; semaglutide generics launched in India and Canada in 2026. Sales DKK 79.1B. | Novo 20-F 2025 CMS: negotiated prices for 2027 |
| 2032 | Tagrisso | AstraZeneca | Oncology | $7.3B | Patent-expiry estimate | No US filing found | – | Core US patents expire in 2032. Later patents cover the formulation (2035) and one approved use (2042). | AZ FY2025 |
| 2032 | Entyvio | Takeda | Immunology | ≈$6.0B | Company guidance | Filed with the FDA | 2028 · pending | Takeda pushed its assumed US biosimilar entry back to 2032 on formulation and manufacturing patents. Sales ¥958.0B (fiscal year to March 2026). | Takeda FY2025 Pharma Japan CMS: drugs selected for 2028 |
| 2032 | Imbruvica | AbbVie / Johnson & Johnson | Oncology | $4.0B | Settlement / court date | Approved, waiting to launch | 2026 · −38% | A court upheld the key patent in 2021; AbbVie expects no US generic before 30 March 2032, assuming pediatric exclusivity. Sales: AbbVie in the US ($2.05B) plus J&J outside the US ($1.93B). The revenue each company reports also includes its share of the other's profit, so the two add up to more. | AbbVie 8-K, Aug 2021 AbbVie 10-K 2025 J&J 10-K 2025 CMS: negotiated prices for 2026 |
| 2032 | Calquence | AstraZeneca | Oncology | $3.5B | Patent-expiry estimate | Filed with the FDA | 2027 · −40% | AstraZeneca lists US patents expiring between 2026 and 2036; generic makers challenged them from 2024. | AstraZeneca 20-F 2025 CMS: negotiated prices for 2027 |
| 2032 | Venclexta | AbbVie | Oncology | $2.8B | Patent-expiry estimate | Approved, waiting to launch | – | Compound patents listed with the FDA run to June 2031 and January 2032, with other patents to 2033. AbbVie books worldwide sales and shares US profit with Roche's Genentech. | AbbVie 10-K 2025 FDA Orange Book: Venclexta patents |
| 2033 | Skyrizi | AbbVie | Immunology | $17.6B | Company guidance | No US filing found | – | AbbVie 10-K: US composition-of-matter patents expire 2033. | AbbVie 10-K |
| 2033 | Erleada | Johnson & Johnson | Oncology | $3.6B | Patent-expiry estimate | Approved, waiting to launch | 2028 · pending | Drug substance patents listed with the FDA run to 2032 and 2033, with use patents to 2041. J&J sued Lupin and Hetero over generic filings; Lupin settled in August 2025 on confidential terms. | J&J 10-K 2025 FDA Orange Book: Erleada patents CMS: drugs selected for 2028 |
| 2034 | Vabysmo | Roche | Other | ≈$4.9B | Patent-expiry estimate | No US filing found | – | The 12-year US biologic exclusivity ends in January 2034. Roche does not publish Vabysmo's patent dates, which may run later. Eye diseases (wet AMD, diabetic macular edema). Sales CHF 4.10B. | Roche Finance Report 2025 FDA Purple Book |
| 2035 | Prevnar 20 | Pfizer | Vaccines | $6.5B | Company guidance | No US filing found | – | Pfizer 10-K: US basic product patent expires 2035. Sales are the whole Prevnar family. | Pfizer 10-K |
| 2035 | Ultomiris | AstraZeneca | Other | $4.7B | Company guidance | No US filing found | – | AstraZeneca 20-F: US patent protection expected to 2035. Rare immune and blood diseases. | AstraZeneca 20-F 2025 |
| 2036 | Mounjaro | Eli Lilly | Cardiometabolic | $23.0B | Company guidance | Filed with the FDA | – | Lilly 10-K: US compound patent expires 2036. Excludes Zepbound, the same molecule sold for obesity. | Lilly 10-K |
| 2036 | Biktarvy | Gilead | Infectious disease | $14.3B | Settlement / court date | Filed with the FDA | 2028 · pending | Settlements bar US generics before 1 April 2036, later than the earlier 2033 estimate. | Gilead FY2025 Fierce Pharma CMS: drugs selected for 2028 |
| 2036 | Zepbound | Eli Lilly | Cardiometabolic | $13.5B | Company guidance | Filed with the FDA | – | Same molecule as Mounjaro (tirzepatide), sold for obesity. Lilly 10-K: US compound patent 2036. | Lilly 10-K 2025 |
| 2036 | Vyvgart | argenx | Neuroscience | $4.2B | Patent-expiry estimate | No US filing found | – | argenx: the US composition-of-matter patent expires in 2036, before any extension, and 12-year biologic exclusivity runs to December 2033. Myasthenia gravis and CIDP. Sales are argenx's product net sales, including Vyvgart Hytrulo. | argenx 20-F 2025 |
| 2037 | Trikafta | Vertex | Other | $10.3B | Patent-expiry estimate | No US filing found | – | Patents run to about 2037. Cystic fibrosis. Excludes the successor Alyftrek ($0.8B). | Vertex FY2025 |
| 2037 | Rinvoq | AbbVie | Immunology | $8.3B | Settlement / court date | Filed with the FDA | – | September 2025 settlements bar US generics before April 2037. Consensus had assumed 2032. | AbbVie 10-K Fierce Pharma |
Writing about the patent cliff? Key figures, ready to cite →